


Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claims 1 to 49. (Cancelled).

50. (Currently amended) A compound of formula Ia,



(Ia)

wherein the compound is in the form of a base or a pharmaceutically acceptable salt thereof, and wherein:

P is a 6-membered ring containing one nitrogen;

R^1 is hydrogen;

R^2 is C_{0-6} alkylcyano;

R^3 is C_{0-6} alkylNR⁴R⁵;

m is 1;

n is 1;

R^4 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, C_{0-6} alkylheteroaryl, C_{1-6} alkylNR¹⁴R¹⁵, and a 5- or 6-

membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

R⁵ is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl, and C₁₋₆alkylNR¹⁴R¹⁵;

or R⁴ and R⁵ together with the N to which they are attached may form a 6-membered heterocyclic group containing one nitrogen and one oxygen; and

wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, and C₀₋₆alkylheteroaryl group defined under R² to R⁵ is optionally substituted by one or more groups Z;

R¹⁴ and R¹⁵ are independently selected from hydrogen, C₁₋₆alkyl, and C₀₋₆alkylC₃₋₆cycloalkyl, wherein R¹⁴ and R¹⁵ optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

Z is independently selected from the group consisting of oxo, halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, C₀₋₆alkylaryl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR¹⁶R¹⁷, NR¹⁶R¹⁷, CONR¹⁶R¹⁷, NR¹⁶(CO)R¹⁷, O(CO)C₁₋₆alkyl, (CO)OC₁₋₆alkyl, COR¹⁶, (SO₂)NR¹⁶R¹⁷, SO₂R¹⁶, SOR¹⁶, (CO)C₁₋₆alkylNR¹⁶R¹⁷, (SO₂)C₁₋₆alkylNR¹⁶R¹⁷, phenyl, heteroaryl, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, heteroaryl, and heterocyclic groups are optionally substituted by a group Y;

Y is selected from the group consisting of oxo, halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, C₀₋₆alkylaryl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR¹⁶R¹⁷, NR¹⁶R¹⁷, CONR¹⁶R¹⁷, NR¹⁶(CO)R¹⁷, O(CO)C₁₋₆alkyl, (CO)OC₁₋₆alkyl, COR¹⁶, (SO₂)NR¹⁶R¹⁷, SO₂R¹⁶, SOR¹⁶, (CO)C₁₋₆alkylNR¹⁶R¹⁷, (SO₂)C₁₋₆alkylNR¹⁶R¹⁷, phenyl, C₀₋₆alkylaryl, and heteroaryl, wherein the phenyl, C₀₋₆alkylaryl, and heteroaryl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, and trifluoromethoxy;

R¹⁶ and R¹⁷ are independently selected from hydrogen and C₁₋₆alkyl, and

wherein R¹⁶ and R¹⁷ optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S.

51. (Previously presented) A compound according to claim 50, wherein:

R⁵ is C₁₋₆alkylNR¹⁴R¹⁵, and

R⁴ is selected from hydrogen, C₁₋₆alkyl; or

R⁴ and R⁵ together with the N to which they are attached form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

and wherein R¹⁴ and R¹⁵ may together form a 5-membered heterocyclic group containing one or more heteroatoms, selected independently from N, and O ;

Y is selected from C₁₋₆alkyl, C₀₋₆alkylaryl, NR¹⁶R¹⁷, phenyl, wherein the phenyl may be optionally substituted with nitro and trifluoromethyl;

wherein R¹⁶ and R¹⁷ may together form a 5-membered heterocyclic group containing one N heteroatom.

52. (Previously presented) A compound according to claim 50, wherein P is pyridyl; R² is CN; R³ is C₀₋₆alkylNR⁴R⁵; wherein R⁴ and R⁵ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

53. (Previously presented) A compound according to claim 52, wherein R⁴ and R⁵ together form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

54. (Previously presented) A compound selected from:

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-5-carbonitrile;

3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;

3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol, or
2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
or a pharmaceutically acceptable salt thereof.

55. (Previously presented) A compound selected from:

2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile;
3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1*H*-indol-2-ol;
5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1*H*-indol-2-ol;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-methyl-*N*-(1-methylpiperidin-4-yl)nicotinamide;
5-Nitro-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indol-2-ol;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;

3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile;
5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol, or
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile;
or a pharmaceutically acceptable salt thereof.

56. (Previously presented) A hydrochloride salt of a compound according to claim 55.

57. (Previously presented) 6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide;
2-Hydroxy-3-(5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl)-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-thiazol-4-yl)-1*H*-indol-2-ol, or
3-{5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
or a pharmaceutically acceptable salt thereof.

58. (Previously presented) A fumarate salt of a compound according to claim 57.

59. (Currently amended) A compound that is 2-Hydroxy-3-{5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile ~~as a free base~~ or a pharmaceutically acceptable salt thereof.

60. (Previously presented) A compound that is 2-Hydroxy-3-[5-(4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl)methyl]pyridin-2-yl]-1*H*-indole-5-carbonitrile ~~as a free base~~ or a pharmaceutically acceptable salt thereof.

61. (Previously presented) A compound that is 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.

62. (Previously presented) A compound that is 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1*H*-indol-2-ol or a pharmaceutically acceptable salt thereof.

63. (Previously presented) A compound that is 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-oxazol-5-yl)-1*H*-indol-2-ol or a pharmaceutically acceptable salt thereof.

64. (Previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 54-63 in association with at least one pharmaceutically acceptable carrier or diluent.